Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
July 22, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
May 15, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
February 13, 2024
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
November 14, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces New CEO
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
October 06, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
September 20, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
August 30, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
August 21, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
February 10, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
January 09, 2023
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
November 10, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
November 01, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
September 26, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
September 26, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022
September 20, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
September 09, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
August 23, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
July 05, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
June 23, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
May 24, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
May 11, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
April 01, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
February 11, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
January 06, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
January 06, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
January 04, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
January 03, 2022
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
November 12, 2021
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose
October 13, 2021
From
Anebulo Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANEB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit